|
Kadcyla: HCP Educational Information
|
|
Tecentriq (atezolizumab)
|
|
Actemra (tocilizumab)
|
|
Systemic and inhaled fluoroquinolones: risk of aortic aneurysm and dissection
|
|
ADENURIC (febuxostat): increased risk of cardiovascular death and all-cause mortality in patients treated with febuxostat in the CARES study
|
|
Lapatinib (Tyverb): important update to Summary of Product Characteristics
|
|
Actemra (tocilizumab): a new important identified risk: hepatotoxicity
|
|
Important information about MabThera
|
|
Actemra (tocilizumab)
|
|
Tecentriq (atezolizumab): a new important identified risk: immune-related myositis
|
